Quarterly ResultNov 5, 2026, 05:01 PM
Starling Oncology Q3 Revenue Up 24.3% to $169.8M; Adj. EBITDA Turns Positive
AI Summary
Starling Oncology, Inc. reported its third quarter 2026 financial results, showing a 24.3% increase in consolidated revenue to $169.8 million and a 62.1% rise in gross profit to $30.7 million. The company narrowed its net loss to $15.7 million and achieved positive Adjusted EBITDA of $3.4 million, a significant improvement from the prior year's loss. Key growth drivers included a 44% year-over-year increase in Specialty Pharmacy revenue and a 40% rise in capitated revenue. The company affirmed its full-year 2026 guidance for revenue and Adjusted EBITDA.
Key Highlights
- Consolidated revenue increased 24.3% year over year to $169.8 million.
- Gross profit increased 62.1% to $30.7 million.
- Net loss narrowed to $15.7 million from $16.5 million in the prior year.
- Adjusted EBITDA turned positive at $3.4 million, compared to a loss of $3.5 million.
- Specialty Pharmacy revenue grew 44% year over year to $109 million.
- Capitated revenue grew 40% year over year.
- Full-year 2026 revenue guidance updated to $650 to $660 million.
- Full-year 2026 Adjusted EBITDA guidance updated to $4 to $6 million.
Price Impact
More from TOI